Procainamide and Quinidine Inhibition of the Human Hepatic Degradation of Meperidine In Vitro

6600 W. Touhy Ave.
Niles, IL 60714
Tel: 847.647.2900
Fax: 847.647.1155
circulation@jatox.com

Published: Journal of Analytical Toxicology, ISSN 0146-4760, Volume 27, Number 3, April 2003, pp. 142-144

Procainamide and Quinidine Inhibition of the Human Hepatic Degradation of Meperidine In Vitro
David N. Bailey and John R. Briggs
Division of Laboratory Medicine, Department of Pathology, University of California, San Diego Medical Center,
200 West Arbor Drive, San Diego, California 92103-8320

Procainamide and quinidine inhibition of the degradation of meperidine in human liver was investigated by incubation of two concentrations of either drug with meperidine in homogenates of human liver over 24 and 36 h. Meperidine concentrations declined by 26% after incubation for 24 h and by 42% after incubation for 36 h. In the presence of procainamide, however, they decreased by only 15% to 18% at 24 h and by only 26% to 28% at 36 h. In the presence of quinidine, they declined by only 18% to 19% at 24 h and by only 27% to 28% at 36 h. Procainamide and quinidine may inhibit human hepatic carboxylesterase hCE-1, which is responsible for catalyzing the hydrolysis of meperidine. This inhibition may prolong the biological half-life of meperidine in patients receiving the drug together with either procainamide or quinidine.

Reproduction of editorial content of this journal is prohibited without publisher’s permission.

This article is available in its entirety by fax for $40.00 each.
Visa, MasterCard and AMEX accepted.

To order electronically click here
or call: 847-647-2900 ext. 1323
or fax request to: 847-647-1155.

To order multiple copies click here.

Please indicate JAT volume and issue along with page numbers.